Supplementary Table S2. Newcastle-Ottawa Scale scores of the included articles in the study.

	Selection (****)				Comparability (**)		Exposure (***)			NOS score
	1	**2**	**3**	**4**	**5**	**6**	**7**	**8**	**9**	
Prieto-Peña, D., Urriago-Gil, J. D., Ocejo-Vinyals, G., García-Ibarbia, C., Salmon-González, Z., Martin-Millán, M., Corrales-Selaya, C., Pulito-Cueto, V., López-Mejías, R., Blanco, R., & Hernandez, J. L. (2025). Genetic Biomarkers for Statin-Induced Myopathy. International journal of molecular sciences, 26(22), 11144. https://doi.org/10.3390/ijms262211144	*	*	*	*			*	*		6
Fukunaga, K., Nakagawa, H., Ishikawa, T., Kubo, M., & Mushiroda, T. (2016). ABCB1 polymorphism is associated with atorvastatin-induced liver injury in Japanese population. BMC genetics, 17(1), 79. https://doi.org/10.1186/s12863-016-0390-5	*	*	*	*			*	*		6
Lönnberg, K. I., Tornio, A., Hirvensalo, P., Keskitalo, J., Mustaniemi, A. L., Kiiski, J. I., Filppula, A. M., & Niemi, M. (2023). Real-world pharmacogenetics of statin intolerance: effects of SLCO1B1, ABCG2 , and CYP2C9 variants. Pharmacogenetics and genomics, 33(7), 153–160. https://doi.org/10.1097/FPC.0000000000000504	*	*	*	*		*	*	*	*	8
Ramakumari, N., Indumathi, B., Katkam, S. K., & Kutala, V. K. (2018). Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian heart journal, 70 Suppl 3(Suppl 3), S120–S125. https://doi.org/10.1016/j.ihj.2018.07.009			*		*	*	*		*	5
Isackson, P. J., Wang, J., Zia, M., Spurgeon, P., Levesque, A., Bard, J., James, S., Nowak, N., Lee, T. K., & Vladutiu, G. D. (2018). RYR1 and CACNA1S genetic variants identified with statin-associated muscle symptoms. Pharmacogenomics, 19(16), 1235–1249. https://doi.org/10.2217/pgs-2018-0106	*	*	*	*			*			5
Hubáček, J. A., Dlouhá, D., Adámková, V., Zlatohlavek, L., Viklický, O., Hrubá, P., Češka, R., & Vrablík, M. (2015). SLCO1B1	*	*	*	*			*	*		6

polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Medical science monitor : international medical journal of experimental and clinical research, 21, 1454–1459. https://doi.org/10.12659/MSM.893007										
Oh, J., Ban, M. R., Miskie, B. A., Pollex, R. L., & Hegele, R. A. (2007). Genetic determinants of statin intolerance. *Lipids in health and disease*, *6*, 7. https://doi.org/10.1186/1476-511X-6-7	*	*	*	*			*	*		6
Türkmen, D., Bowden, J., Masoli, J. A. H., Melzer, D., & Pilling, L. C. (2024). SLCO1B1 Exome Sequencing and Statin Treatment Response in 64,000 UK Biobank Patients. International journal of molecular sciences, 25(8), 4426. https://doi.org/10.3390/ijms25084426	*	*	*	*	*	*	*	*	*	9
Lu, B., Sun, L., Seraydarian, M., Hoffmann, T. J., Medina, M. W., Risch, N., Iribarren, C., Krauss, R. M., & Oni-Orisan, A. (2021). Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin. Clinical pharmacology and therapeutics, 110(3), 733–740. https://doi.org/10.1002/cpt.2337	*	*	*		*	*	*	*	*	8
Voora, D., Baye, J., McDermaid, A., Narayana Gowda, S., Wilke, R. A., Nicole Myrmoe, A., Hajek, C., & Larson, E. A. (2022). SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care. Clinical pharmacology and therapeutics, 111(5), 1075–1083. https://doi.org/10.1002/cpt.2527	*	*	*	*	*	*	*	*	*	9
Bakar, N. S., Neely, D., Avery, P., Brown, C., Daly, A. K., & Kamali, F. (2018). Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study. Clinical pharmacology and therapeutics, 104(1), 178–187. https://doi.org/10.1002/cpt.887	*	*	*	*	*	*	*	*		8
Merćep, I., Radman, I., Trkulja, V., Božina, T., Šimičević, L., Budimir, E., Ganoci, L., & Božina, N. (2022). Loss of function polymorphisms in SLCO1B1 (c.521T>C, rs4149056) and ABCG2 (c.421C>A, rs2231142) genes are associated with adverse events of rosuvastatin: a case-control study. *European journal of clinical*	*	*	*	*	*	*	*	*		8

pharmacology, *78*(2), 227–236. https://doi.org/10.1007/s00228-021-03233-7										
Linskey, D. W., English, J. D., Perry, D. A., Ochs-Balcom, H. M., Ma, C., Isackson, P. J., Vladutiu, G. D., & Luzum, J. A. (2020). Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms. *Pharmacogenetics and genomics*, *30*(9), 208–211. https://doi.org/10.1097/FPC.0000000000000412	*	*	*	*	*	*	*	*		8
Frudakis, T. N., Thomas, M. J., Ginjupalli, S. N., Handelin, B., Gabriel, R., & Gomez, H. J. (2007). CYP2D6*4 polymorphism is associated with statin-induced muscle effects. *Pharmacogenetics and genomics*, *17*(9), 695–707. https://doi.org/10.1097/FPC.0b013e328012d0a9		*	*	*	*		*	*		6
Jansen, M. E., Rigter, T., Fleur, T. M. C., Souverein, P. C., Verschuren, W. M. M., Vijverberg, S. J., Swen, J. J., Rodenburg, W., & Cornel, M. C. (2023). Predictive Value of *SLCO1B1* c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users. *Genes*, *14*(2), 456. https://doi.org/10.3390/genes14020456	*	*	*	*	*	*	*	*		8
Lalatović, N., Ždralević, M., Antunović, T., & Pantović, S. (2023). Genetic polymorphisms in ABCB1 are correlated with the increased risk of atorvastatin-induced muscle side effects: a cross-sectional study. *Scientific reports*, *13*(1), 17895. https://doi.org/10.1038/s41598-023-44792-2	*	*	*	*	*	*	*	*		8
Dheyaa Aziz, N., Abbood, S. H., Al-Mayali, A. H., & Hadi, N. R. (2023). ASSOCIATION OF SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1 GENE POLYMORPHISM WITH RESPONSE TO ATORVASTATIN AND ASSOCIATED MYOPATHY IN IRAQI DYSLIPIDEMIA PATIENTS. *Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego*, *51*(5), 496–503. https://doi.org/10.36740/Merkur202305108	*	*	*	*			*	*		6

Neřoldová, M., Stránecký, V., Hodaňová, K., Hartmannová, H., Piherová, L., Přistoupilová, A., Mrázová, L., Vrablík, M., Adámková, V., Hubáček, J. A., Jirsa, M., & Kmoch, S. (2016). Rare variants in known and novel candidate genes predisposing to statin-associated myopathy. *Pharmacogenomics*, *17*(13), 1405–1414. https://doi.org/10.2217/pgs-2016-0071	*	*	*				*	*		5
Alghalyini, B., El Shamieh, S., Salami, A., Visvikis Siest, S., Fakhoury, H. M., & Fakhoury, R. (2018). Effect of SLCO1B1 gene polymorphisms and vitamin D on statin-induced myopathy. *Drug metabolism and personalized therapy*, *33*(1), 41–47. https://doi.org/10.1515/dmpt-2017-0030		*	*	*			*	*		5
Ferrari, M., Guasti, L., Maresca, A., Mirabile, M., Contini, S., Grandi, A. M., Marino, F., & Cosentino, M. (2014). Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. *European journal of clinical pharmacology*, *70*(5), 539–547. https://doi.org/10.1007/s00228-014-1661-6	*	*	*	*	*	*	*	*		8
Mirošević Skvrce, N., Macolić Šarinić, V., Šimić, I., Ganoci, L., Muačević Katanec, D., & Božina, N. (2015). ABCG2 gene polymorphisms as risk factors for atorvastatin adverse reactions: a case-control study. *Pharmacogenomics*, *16*(8), 803–815. https://doi.org/10.2217/pgs.15.47	*	*	*	*	*	*	*	*		8
Zakria, M., Hussain, A., Ahmad, N., Ahmed, N., Rauf, M. A., & Siraj, S. (2023). The lipid-lowering efficacy of rosuvastatin is associated with variations in SLCO1B1: a 12-month prospective cohort study. *European review for medical and pharmacological sciences*, *27*(10), 4708–4717. https://doi.org/10.26355/eurrev_202305_32483	*	*	*				*	*		5
Haldar, T., Kvale, M., Yang, J., Douglas, M. P., Coyote-Maetas, W., Kachuri, L., Witte, J. S., Iribarren, C., Medina, M. W., Krauss, R. M., Yee, S. W., & Oni-Orisan, A. (2025). SLCO1B1 Functional Variants, Bilirubin, Statin-Induced Myotoxicity, and Recent Sub-Saharan African Ancestry: A Precision Medicine Health Equity	*	*	*	*	*	*	*		*	8

Study. *Clinical pharmacology and therapeutics*, *117*(6), 1696–1705. https://doi.org/10.1002/cpt.3624										
Liu, J. E., Liu, X. Y., Chen, S., Zhang, Y., Cai, L. Y., Yang, M., Lai, W. H., Ren, B., & Zhong, S. L. (2017). SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study. *European journal of clinical pharmacology*, *73*(11), 1409–1416. https://doi.org/10.1007/s00228-017-2318-z	*	*	*	*	*	*	*	*		8
Zhang, L., Lv, H., Zhang, Q., Wang, D., Kang, X., Zhang, G., & Li, X. (2019). Association of SLCO1B1 and ABCB1 Genetic Variants with Atorvastatin-induced Myopathy in Patients with Acute Ischemic Stroke. *Current pharmaceutical design*, *25*(14), 1663–1670. https://doi.org/10.2174/1381612825666190705204614	*	*	*	*	*	*	*	*		8
Elam, M. B., Majumdar, G., Mozhui, K., Gerling, I. C., Vera, S. R., Fish-Trotter, H., Williams, R. W., Childress, R. D., & Raghow, R. (2017). Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. *PloS one*, *12*(8), e0181308. https://doi.org/10.1371/journal.pone.0181308	*	*	*	*			*	*		6
Sai, K., Kajinami, K., Akao, H., Iwadare, M., Sato-Ishida, R., Kawai, Y., Takeda, K., Tanimoto, T., Yamano, T., Akasaka, T., Ishida, T., Hirata, K. I., Saku, K., Yagi, S., Soeki, T., Sata, M., Ueno, M., Miyazaki, S., Shiraki, A., Oyama, J. I., … Saito, Y. (2016). A possible role for HLA-DRB1*04:06 in statin-related myopathy in Japanese patients. *Drug metabolism and pharmacokinetics*, *31*(6), 467–470. https://doi.org/10.1016/j.dmpk.2016.09.002	*	*	*	*			*	*		6
Brunham, L. R., Lansberg, P. J., Zhang, L., Miao, F., Carter, C., Hovingh, G. K., Visscher, H., Jukema, J. W., Stalenhoef, A. F., Ross, C. J., Carleton, B. C., Kastelein, J. J., & Hayden, M. R. (2012). Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. *The pharmacogenomics journal*, *12*(3), 233–237. https://doi.org/10.1038/tpj.2010.92	*	*	*		*	*	*	*		7

Bai, X., Zhang, B., Wang, P., Wang, G. L., Li, J. L., Wen, D. S., Long, X. Z., Sun, H. S., Liu, Y. B., Huang, M., & Zhong, S. L. (2019). Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites. *Acta pharmacologica Sinica*, *40*(4), 492–499. https://doi.org/10.1038/s41401-018-0013-y	*	*	*	*	*	*	*	*	*	9
Becker, M. L., Elens, L. L., Visser, L. E., Hofman, A., Uitterlinden, A. G., van Schaik, R. H., & Stricker, B. H. (2013). Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. *The pharmacogenomics journal*, *13*(3), 251–256. https://doi.org/10.1038/tpj.2011.59	*	*	*	*	*	*	*	*	*	9
Marciante, K. D., Durda, J. P., Heckbert, S. R., Lumley, T., Rice, K., McKnight, B., Totah, R. A., Tamraz, B., Kroetz, D. L., Fukushima, H., Kaspera, R., Bis, J. C., Glazer, N. L., Li, G., Austin, T. R., Taylor, K. D., Rotter, J. I., Jaquish, C. E., Kwok, P. Y., Tracy, R. P., … Psaty, B. M. (2011). Cerivastatin, genetic variants, and the risk of rhabdomyolysis. *Pharmacogenetics and genomics*, *21*(5), 280–288. https://doi.org/10.1097/FPC.0b013e328343dd7d	*		*	*	*	*	*	*		7
Santos, P. C., Gagliardi, A. C., Miname, M. H., Chacra, A. P., Santos, R. D., Krieger, J. E., & Pereira, A. C. (2012). SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. *European journal of clinical pharmacology*, *68*(3), 273–279. https://doi.org/10.1007/s00228-011-1125-1	*	*	*	*	*	*	*	*	*	9
Hoenig, M. R., Walker, P. J., Gurnsey, C., Beadle, K., & Johnson, L. (2011). The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. *Journal of clinical lipidology*, *5*(2), 91–96. https://doi.org/10.1016/j.jacl.2011.01.001	*	*	*	*		*	*		*	7
Ruaño, G., Thompson, P. D., Windemuth, A., Seip, R. L., Dande, A., Sorokin, A., Kocherla, M., Smith, A., Holford, T. R., & Wu, A. H. (2007). Physiogenomic association of statin-related myalgia to		*	*	*	*	*	*	*		7

serotonin receptors. *Muscle & nerve*, *36*(3), 329–335. https://doi.org/10.1002/mus.20871										
Zuccaro, P., Mombelli, G., Calabresi, L., Baldassarre, D., Palmi, I., & Sirtori, C. R. (2007). Tolerability of statins is not linked to CYP450 polymorphisms, but reduced CYP2D6 metabolism improves cholesteraemic response to simvastatin and fluvastatin. *Pharmacological research*, *55*(4), 310–317. https://doi.org/10.1016/j.phrs.2006.12.009	*	*	*	*	*	*	*	*		8
Sharif, M., Farhat, K., Noor, M., Ahmad, A. M., Khan, D. A., Afzal, R. K., & Siddique, M. B. (2025). Association of ABCG2 421G>T (rs2231142) Polymorphism with rosuvastatin induced adverse effects in dyslipidemic patients: Implication for personalized medicine. *PloS one*, *20*(10), e0334600. https://doi.org/10.1371/journal.pone.0334600		*	*	*	*	*	*			6
Ovesjö, M. L., Skilving, I., Bergman, P., Rane, A., Ekström, L., & Björkhem-Bergman, L. (2016). Low Vitamin D Levels and Genetic Polymorphism in the Vitamin D Receptor are Associated with Increased Risk of Statin-Induced Myopathy. *Basic & clinical pharmacology & toxicology*, *118*(3), 214–218. https://doi.org/10.1111/bcpt.12482	*	*	*	*			*	*		6
Miroševic Skvrce, N., Božina, N., Zibar, L., Barišic, I., Pejnovic, L., & Macolic Šarinic, V. (2013). CYP2C9 and ABCG2 polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case-control study. *Pharmacogenomics*, *14*(12), 1419–1431. https://doi.org/10.2217/pgs.13.135	*	*	*	*	*	*	*	*		8
Wilke, R. A., Moore, J. H., & Burmester, J. K. (2005). Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. *Pharmacogenetics and genomics*, *15*(6), 415–421. https://doi.org/10.1097/01213011-200506000-00007	*	*	*	*			*	*		6
Ruaño, G., Windemuth, A., Wu, A. H., Kane, J. P., Malloy, M. J., Pullinger, C. R., Kocherla, M., Bogaard, K., Gordon, B. R., Holford, T. R., Gupta, A., Seip, R. L., & Thompson, P. D. (2011).	*	*	*	*	*	*	*	*		8

Mechanisms of statin-induced myalgia assessed by physiogenomic associations. *Atherosclerosis*, *218*(2), 451–456. https://doi.org/10.1016/j.atherosclerosis.2011.07.007										
Nicoletti, P., Aithal, G. P., Bjornsson, E. S., Andrade, R. J., Sawle, A., Arrese, M., Barnhart, H. X., Bondon-Guitton, E., Hayashi, P. H., Bessone, F., Carvajal, A., Cascorbi, I., Cirulli, E. T., Chalasani, N., Conforti, A., Coulthard, S. A., Daly, M. J., Day, C. P., Dillon, J. F., Fontana, R. J., … International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium (2017). Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. *Gastroenterology*, *152*(5), 1078–1089. https://doi.org/10.1053/j.gastro.2016.12.016	*	*	*	*			*	*		6
Isackson, P. J., Ochs-Balcom, H. M., Ma, C., Harley, J. B., Peltier, W., Tarnopolsky, M., Sripathi, N., Wortmann, R. L., Simmons, Z., Wilson, J. D., Smith, S. A., Barboi, A., Fine, E., Baer, A., Baker, S., Kaufman, K., Cobb, B., Kilpatrick, J. R., & Vladutiu, G. D. (2011). Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional functions of EYS. *Muscle & nerve*, *44*(4), 531–538. https://doi.org/10.1002/mus.22115	*	*	*	*	*		*	*		7
Giannakopoulou, E., Ragia, G., Kolovou, V., Tavridou, A., Tselepis, A. D., Elisaf, M., Kolovou, G., & Manolopoulos, V. G. (2014). No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. *Molecular biology reports*, *41*(7), 4631–4638. https://doi.org/10.1007/s11033-014-3334-z	*	*	*	*	*	*	*	*	*	9
Al-Salameh, A., Danchin, N., Verstuyft, C., Kotti, S., Puymirat, E., Ferrières, J., Schiele, F., Coste, P., Lemesle, G., Cayla, G., Becquemont, L., & Simon, T. (2020). Association between rs4149056 variant in *SLCO1B1* and early discontinuation of statin after acute myocardial infarction. *Pharmacogenomics*, *21*(3), 163–	*	*	*	*	*	*	*		*	8

172. https://doi.org/10.2217/pgs-2019-0109										
Donnelly, L. A., Doney, A. S., Tavendale, R., Lang, C. C., Pearson, E. R., Colhoun, H. M., McCarthy, M. I., Hattersley, A. T., Morris, A. D., & Palmer, C. N. (2011). Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study. *Clinical pharmacology and therapeutics*, *89*(2), 210–216. https://doi.org/10.1038/clpt.2010.255	*	*	*	*	*	*	*			7
Voora, D., Shah, S. H., Spasojevic, I., Ali, S., Reed, C. R., Salisbury, B. A., & Ginsburg, G. S. (2009). The SLCO1B1*5 genetic variant is associated with statin-induced side effects. *Journal of the American College of Cardiology*, *54*(17), 1609–1616. https://doi.org/10.1016/j.jacc.2009.04.053	*	*	*	*		*	*		*	7
Murphy, W. A., Lin, N., Damask, A., Schwartz, G. G., Steg, P. G., Szarek, M., Banerjee, P., Fazio, S., Manvelian, G., Pordy, R., Shuldiner, A. R., & Paulding, C. (2022). Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial. *Circulation. Genomic and precision medicine*, *15*(3), e003503. https://doi.org/10.1161/CIRCGEN.121.003503	*	*	*	*	*	*	*		*	8
Hubacek, J. A., Adamkova, V., Zlatohlavek, L., Steiner-Mrazova, L., & Vrablik, M. (2017). COQ2 polymorphisms are not associated with increased risk of statin-induced myalgia/myopathy in the Czech population. *Drug metabolism and personalized therapy*, *32*(4), 177–182. https://doi.org/10.1515/dmpt-2017-0027	*	*	*	*			*	*		6
K Siddiqui, M., Maroteau, C., Veluchamy, A., Tornio, A., Tavendale, R., Carr, F., Abelega, N. U., Carr, D., Bloch, K., Hallberg, P., Yue, Q. Y., Pearson, E. R., Colhoun, H. M., Morris, A. D., Dow, E., George, J., Pirmohamed, M., Ridker, P. M., Doney, A. S. F., Alfirevic, A., … PREDICTION-ADR Consortium (2017). A common missense variant of LILRB5 is associated with statin intolerance and myalgia. European heart journal, 38(48), 3569–3575.	*	*	*	*	*	*	*	*		8

https://doi.org/10.1093/eurheartj/ehx467										
Danik, J. S., Chasman, D. I., MacFadyen, J. G., Nyberg, F., Barratt, B. J., & Ridker, P. M. (2013). Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy. *American heart journal*, *165*(6), 1008–1014. https://doi.org/10.1016/j.ahj.2013.01.025	*	*	*	*				*	*	6
SEARCH Collaborative Group, Link, E., Parish, S., Armitage, J., Bowman, L., Heath, S., Matsuda, F., Gut, I., Lathrop, M., & Collins, R. (2008). SLCO1B1 variants and statin-induced myopathy--a genomewide study. *The New England journal of medicine*, *359*(8), 789–799. https://doi.org/10.1056/NEJMoa0801936	*	*	*	*	*		*	*		7
Farooq, T., Naeem, U., Siddique, A., Kausar, S., Waheed, A., & Mumal, S. (2025). Impact of SLCO1B1 (rs2306283) polymorphism on personalized atorvastatin dosing in a genetically distinct South Asian cohort. BMC pharmacology & toxicology, 26(1), 189. https://doi.org/10.1186/s40360-025-01022-x	*	*	*		*		*		*	6
Alqasrawi, M. N., Al-Mahayri, Z. N., AlBawa'neh, A. S., Khasawneh, L. Q., Dabaghie, L., Altoum, S. M., Hamza, D., Misra, V., Ouda, H., Aburuz, S., Al-Maskari, F., AlKaabi, J., Patrinos, G. P., & Ali, B. R. (2025). Pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects: a prospective observational study in the UAE's multiethnic population. Human genomics, 19(1), 44. https://doi.org/10.1186/s40246-025-00753-6	*	*	*	*	*	*	*	*	*	9
Ahmed Feldman, M., Billman, K., Sennoun, M., Ng, G., Hussain, M., Schlosser, E. G., Hincapie, A. L., & Allen, J. D. (2025). Retrospective Evaluation of the Impact of *SLCO1B1* Variation on Statin Effectiveness. *Journal of personalized medicine*, *15*(11), 511. https://doi.org/10.3390/jpm15110511		*	*	*		*	*		*	6
Lauritzen, T., Munkhaugen, J., Bergan, S., Peersen, K., Svarstad, A. C., Andersen, A. M., Pahnke, J., Husebye, E., & Vethe, N. T. (2024). The atorvastatin metabolite pattern in muscle tissue and blood plasma is associated with statin muscle side effects in patients with coronary heart disease; An exploratory case-control	*	*	*	*			*	*		6

study. Atherosclerosis plus, 55, 31–38. https://doi.org/10.1016/j.athplu.2024.01.001										
Park, Y. A., Chang, Y., Lee, D. H., Kim, J. S., Park, M., Choi, S. A., Song, T. J., & Gwak, H. S. (2024). Association between coenzyme Q 10-related genetic polymorphisms and statin-associated myotoxicity in Korean stroke patients. Frontiers in pharmacology, 15, 1358567. https://doi.org/10.3389/fphar.2024.1358567	*	*	*	*	*	*	*	*		8
Melhem, A. L., Chourasia, M. K., Bigossi, M., Maroteau, C., Taylor, A., Pola, R., Dawed, A. Y., Tornio, A., Palmer, C. N. A., & Siddiqui, M. K. (2021). Common Statin Intolerance Variants in *ABCB1* and *LILRB5* Show Synergistic Effects on Statin Response: An Observational Study Using Electronic Health Records. *Frontiers in genetics*, *12*, 713181. https://doi.org/10.3389/fgene.2021.713181	*	*	*	*		*	*	*	*	8
Shahrure, Z. M., Irshaid, Y. M., Mustafa, K. N., Abujbara, M. A., Al Shhab, M., El-Khateeb, M. S., & Ajlouni, K. M. (2021). SLCO1B1 Gene Polymorphisms (rs2306283 and rs4149056) and Statin-Induced Myopathy in Jordanian Diabetics. Current reviews in clinical and experimental pharmacology, 16(3), 281–288. https://doi.org/10.2174/1574884715666200827105612	*	*	*	*			*	*		6
Association between variants of COQ2 and TNF-α genes and statin-induced toxicities in Bangladeshi hyperlipidemic patients	*	*	*	*	*		*	*		7
Dirjal, A. H., Hussain, D. A. A., & Sahib, A. S. (2019). THE FREQUENCY OF THE SLCO1B1 GENE SNP521T< C AND MYOPATHY IN A SAMPLE OF ARAB IRAQI PATIENTS. *Biochemical & Cellular Archives*, *19*(1).	*	*	*	*			*	*		6
Khine, H., Yuet, W. C., Adams-Huet, B., & Ahmad, Z. (2016). Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia. *American heart journal*, *179*, 1–9. https://doi.org/10.1016/j.ahj.2016.05.015	*	*	*		*	*	*	*	*	8
Luzum, J. A., Kitzmiller, J. P., Isackson, P. J., Ma, C., Medina, M. W., Dauki, A. M., Mikulik, E. B., Ochs-Balcom, H. M., & Vladutiu, G. D. (2015). GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis	*	*	*	*	*	*	*	*		8

of 715 dyslipidemic individuals. *Cell metabolism*, *21*(4), 622–627. https://doi.org/10.1016/j.cmet.2015.03.003										
Carr, D. F., O'Meara, H., Jorgensen, A. L., Campbell, J., Hobbs, M., McCann, G., van Staa, T., & Pirmohamed, M. (2013). SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. *Clinical pharmacology and therapeutics*, *94*(6), 695–701. https://doi.org/10.1038/clpt.2013.161	*	*	*	*		*	*	*		7
Poduri, A., Khullar, M., Bahl, A., Sehrawat, B. S., Sharma, Y., & Talwar, K. K. (2010). Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. *DNA and cell biology*, *29*(10), 629–637. https://doi.org/10.1089/dna.2009.1008	*	*	*	*	*		*	*	*	8
Gao, Y., Zhang, L. R., & Fu, Q. (2008). CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. *European journal of clinical pharmacology*, *64*(9), 877–882. https://doi.org/10.1007/s00228-008-0502-x	*	*	*	*	*	*	*		*	8
Zhang, W., Chen, B. L., Ozdemir, V., He, Y. J., Zhou, G., Peng, D. D., Deng, S., Xie, Q. Y., Xie, W., Xu, L. Y., Wang, L. C., Fan, L., Wang, A., & Zhou, H. H. (2007). SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. *British journal of clinical pharmacology*, *64*(3), 346–352. https://doi.org/10.1111/j.1365-2125.2007.02892.x		*	*	*			*		*	5

The numbered columns correspond to the individual New Castle-Ottawa Scale (NOS) items for case control or cohort scale assessment criteria, with the full criterion titles provide below:

1. Representativeness of the cases or election of the non-exposed cohort
2. Selection of Control or ascertainment of exposure
3. Definition of Controls or demonstration that outcome of interest was not present at start of study

4. Comparability of cases and controls or comparability of cohorts based on the age and gender
5. Comparability of cases and controls or comparability of cohorts based on statin dose, comorbidities or genes
6. Ascertainment of exposure or assessment of outcome
7. Same method of ascertainment for cases and controls or the follow-up long enough for outcomes to occurrence
8. Non-Response rate or adequacy of follow up of cohorts